1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciz398" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciz398</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S40-S47
Volume
69
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
Publisher
An entity responsible for making the resource available
Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-08
Subject
The topic of the resource
COMMUNICABLE diseases; community-acquired bacterial pneumonia; COMMUNITY-acquired pneumonia; DENTAL discoloration; omadacycline; PATIENT safety; safety; skin and skin structure infections; SKIN diseases; TEETH abnormalities; TETRACYCLINE; THERAPEUTIC use
Creator
An entity primarily responsible for making the resource
Opal Steven; File Thomas M; van der Poll Tom; Tzanis Evan; Chitra Surya; McGovern Paul C
Description
An account of the resource
Omadacycline is a semisynthetic tetracycline antibiotic. Phase III clinical trial results have shown that omadacycline has an acceptable safety profile in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Similar to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotransferases were the most frequent treatment-emergent adverse events in phase III studies but were not treatment limiting. Package insert warnings and precautions for omadacycline include tooth discoloration; enamel hypoplasia; inhibition of bone growth following use in late pregnancy, infancy, or childhood up to 8 years of age; an imbalance in mortality (2%, compared with 1% in moxifloxacin-treated patients) was observed in the phase III study in patients with community-acquired bacterial pneumonia. Omadacycline has no effect on the QT interval, and its affinity for muscarinic M2 receptors resulted in transient heart rate increases following dosing.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciz398" target="_blank" rel="noreferrer noopener">10.1093/cid/ciz398</a>
2019
Chitra Surya
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Communicable Diseases
community-acquired bacterial pneumonia
Community-acquired pneumonia
DENTAL discoloration
Department of Internal Medicine
File Thomas M
McGovern Paul C
NEOMED College of Medicine
omadacycline
Opal Steven
Patient Safety
Safety
September 2019 Update
skin and skin structure infections
Skin Diseases
TEETH abnormalities
tetracycline
THERAPEUTIC use
Tzanis Evan
van der Poll Tom
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciz816" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciz816</a>
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
Publisher
An entity responsible for making the resource available
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-09
Subject
The topic of the resource
aminoglycoside; ceftolozane; multidrug resistant; polymyxin; Pseudomonas
October 2019 Update
Creator
An entity primarily responsible for making the resource
Pogue Jason M; Kaye Keith S; Veve Michael P; Patel Twisha S; Gerlach Anthony T; Davis Susan L; Puzniak Laura A; File Tom M; Olson Shannon; Dhar Sorabh; Bonomo Robert A; Perez Federico
Description
An account of the resource
BACKGROUND: Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown. METHODS: A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality. RESULTS: A total of 200 patients were included (100 in each treatment arm). The cohort represented an ill population with 69% in the intensive care unit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset. The most common infection type was ventilator-associated pneumonia (52%); 7% of patients were bacteremic. Combination therapy was more commonly used in polymyxin/aminoglycoside patients than those who received ceftolozane/tazobactam (72% vs 15%, P < .001). After adjusting for differences between groups, receipt of ceftolozane/tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence interval [CI], 1.31-5.30) and protective against AKI (aOR, 0.08; 95% CI, 0.03-0.22). There was no difference in in-hospital mortality. The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the number needed to harm with AKI with a polymyxin/aminoglycoside was 4. CONCLUSIONS: These data support the preferential use of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciz816" target="_blank" rel="noreferrer noopener">10.1093/cid/ciz816</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2019
aminoglycoside
Bonomo Robert A
ceftolozane
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Davis Susan L
Department of Internal Medicine
Dhar Sorabh
File Tom M
Gerlach Anthony T
Kaye Keith S
multidrug resistant
NEOMED College of Medicine
October 2019 Update
Olson Shannon
Patel Twisha S
Perez Federico
Pogue Jason M
polymyxin
Pseudomonas
Puzniak Laura A
Veve Michael P
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciz528" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciz528</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The Pitt Bacteremia Score Predicts Mortality in Non-Bacteremic Infections.
Publisher
An entity responsible for making the resource available
Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-06
Creator
An entity primarily responsible for making the resource
Henderson Heather; Luterbach Courtney L; Cober Eric; Richter Sandra S; Salata Robert A; Kalayjian Robert C; Watkins Richard R; Doi Yohei; Kaye Keith S; Evans Scott; Fowler Vance G; Bonomo Robert A; Harris Anthony; Napravnik Sonia; van Duin David
Description
An account of the resource
Background: Predicting mortality risk in patients is important in research settings. The Pitt bacteremia score (PBS) is commonly used as a predictor of early mortality risk in patients with bloodstream infections (BSI). Here, we determined whether the PBS predicts 14-day inpatient mortality in non-bacteremia carbapenem-resistant Enterobacteriaceae (CRE) infections.; Methods: Patients were selected from the Consortium on resistance against carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE-1), a prospective, multicenter, observational study. We estimated risk ratios to analyze the predictive ability of the PBS overall and each of its components individually. We analyzed each component of the PBS in the prediction of mortality, assessed the appropriate cutoff value for the dichotomized score, and compared the predictive ability of the qPitt score to that of the PBS.; Results: In a cohort of 475 patients with CRE infections, a PBS ≥ 4 was associated with mortality in patients with non-bacteremia infections (RR=21.9 [95% CI: 7.0, 68.8]) and with BSI (RR=6.0 [95% CI: 2.5, 14.4]). In multivariable analysis, the hypotension, mechanical ventilation, mental status, and cardiac arrest parameters of the PBS were independent risk factors for 14-day all-cause inpatient mortality. The temperature parameter as originally calculated for the PBS was not independently associated with mortality. However, a temperature < 36.0ᴼ C versus ≥ 36ᴼ C was independently associated with mortality. A qPitt score ≥ 2 had similar discrimination as a PBS ≥ 4 in non-bacteremia infections.; Conclusion: Here, we validated that the PBS and qPitt score can be used as reliable predictors of mortality in non-bacteremia CRE infections.; © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciz528" target="_blank" rel="noreferrer noopener">10.1093/cid/ciz528</a>
2019
Bonomo Robert A
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Cober Eric
Department of Family & Community Medicine
Department of Internal Medicine
Doi Yohei
Evans Scott
Fowler Vance G
Harris Anthony
Henderson Heather
Kalayjian Robert C
Kaye Keith S
Luterbach Courtney L
Napravnik Sonia
NEOMED College of Medicine
Richter Sandra S
Salata Robert A
September 2019 Update
van Duin David
Watkins Richard R